Disclaimer | LogIn     
1546-2080 Online :: 1546-203X Print
Raising Venture Capital for a Nanoparticle Therapeutics Company
Volume 5, Issue 2

Mark J. Graffagnini, Wilson Sonsini Goodrich & Rosati, P.C.

Several notable venture capital investments have been made in the last twelve months in early stage companies developing nanoparticle therapeutics. Examples include BIND Biosciences, Ensysce Biosciences, Carigent Therapeutics, NanoMed Pharmaceuticals, and Tempo Pharmaceuticals. In this article, corporate attorney Mark J. Graffagnini explains why nanoparticle therapeutic companies generally require considerable venture capital financing, surveys recent deals, and discusses how venture investors are likely to assess the value of such companies. He also describes typical conditions of investment in these types of early stage companies, including board control, operating conditions, and preferred stock rights.

Full Text (PDF)
Home   :   Aims & Scope    :   Editorial Board    :   Subscriptions   :   Partnerships  :   Contact Us
Nanotechnology Law & Business Copyright 2005